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Autoimmune depigmentation of the skin, vitiligo,
a¥icts a considerable number of people, yet no e¡ective
therapeutic modalities have been developed to treat it.
In part, this can be attributed to the obscure etiology
of the disease, which has begun to reveal itself only re-
cently. It is known that pigment is lost as a function of
reduced melanocyte numbers in the epidermis, and that
depigmentation is accompanied by T cell in£ux to the
skin in the vast majority of patients. Characterizing
such in¢ltrating Tcells as type 1 proin£ammatory cyto-
kine-secreting cells reactive with melanocyte-speci¢c
antigen is a major step toward e¡ective therapy. Mela-
noma research has shown that di¡erentiation antigens,
also expressed by normal melanocytes, can be immu-
nogenic when expressed in the melanosomal compart-
ment of the cell. Similar reactivity to melanosomal
antigens is apparent for T cells in¢ltrating vitiligo skin.
It may eventually be possible to treat patients with de-
coy antigens that anergize such Tcells, or to prevent re-
cruitment of the T cells to the skin altogether. In this
respect, it is important that T cells are recruited to the
skin as a function of dendritic cell activation and that
dendritic cells are likely activated at sites of epidermal
trauma as a consequence of stress proteins that spill over
into the microenvironment. Stress proteins chaperon-
ing antigens representative of the cells from which they
were derived are then processed by dendritic cells and
contribute to their activation. Activated dendritic cells
not only migrate to draining lymph nodes to recruit T
cells but may execute cytotoxic e¡ector functions as
well.The contribution of the e¡ector functions to actual
depigmentation of the skin remains to be investigated.
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V
itiligo presents with gradual skin depigmentation
(Das et al, 2001). Its etiopathology is plausibly ex-
plained by the autoimmune theory (Das et al, 2001).
Research supporting autoimmunity is highlighted
here, following an overview of general aspects of
this disorder. Genes associated with vitiligo are subsequently ex-
plored, as they appear to support a role for the immune system in
gradual depigmentation. Selective elimination of melanocytes
from vitiligo skin has led many to believe that these melanocytes
are more prone to undergo cell death, and research ¢ndings along
this line are discussed. Melanocyte death can induce a humoral
immune response through the release of previously sequestered
intracellular antigens; data are reviewed relating to humoral re-
sponses, as are novel ¢ndings suggesting that cytotoxic T cells
can eliminate melanocytes from the basal layer of the epidermis.
The question of how an autoimmune response is initiated re-
mains. Ongoing research is presented suggesting that stress-in-
duced dendritic cell activation may contribute to this process.
Finally, a parallel is drawn between autoimmunity to melano-
cytes and tumor immunity to melanoma cells, in keeping with
the emerging view that knowledge regarding immune responses
to melanocytic cells can support the development of e¡ective im-
munotherapy for both vitiligo and melanoma.
GRADUAL SKIN DEPIGMENTATION
Approximately 1% of the world population is subject to gradual
depigmentation of the skin (Das et al, 2001). The associated skin
disorder vitiligo strikes both genders and all races and can initiate
at any age (Das et al, 2001). Depigmentation is more apparent in
individuals of darker skin tones, yet vitiligo can be equally trau-
matizing for light- skinned individuals (Fig 1). The spotted ap-
pearance of patients resembles tuberculoid leprosy; thus, vitiligo
is especially stigmatizing in countries where leprosy prevails (Or-
tonne et al, 1983). Surprisingly, there is little evidence that loss of
melanocytes leaves depigmented skin more susceptible to UV-
mediated skin damage and the development of skin cancer
(Schallreuter et al, 2002).
It is imperative that we gain an understanding of the immuno-
pathogenesis of vitiligo to enable development of e¡ective
therapy aimed at halting depigmentation and inducing
repigmentation. Starting with evidence in support of the centri-
fugal removal of melanocytes from the basal layer of the epider-
mis during active disease, research has revealed that progressive,
generalized vitiligo involves skin in¢ltration by immunocytes,
including cytotoxic CD8 T cells (Le Poole et al, 1993; Le Poole
et al, 1996; van denWijngaard et al, 2000). New lesions typically
develop following a traumatic event to the skinfor example,
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UVoverexposure, contact with bleaching phenols, or skin injuries
such as burns and cuts. Depigmentation ensues only in a subset
of individuals prone to develop vitiligo (Das et al, 2001); conse-
quently, a hereditary component to this disease has been the sub-
ject of intense investigation.
GENETIC PREDISPOSITION
The prevalence of vitiligo is markedly increased in some commu-
nities where consanguinial marriages are common. For example,
within a community in Bangalore, India, up to one in every ¢ve
individuals develops depigmented skin lesions (Ramaiah et al,
1988). Vitiligo is also more prevalent among autoimmune pa-
tients, particularly those with autoimmune thyroiditis (Hegedus
et al, 1994). Moreover, an association with speci¢c HLA haplo-
types has been demonstrated within several populations (Venne-
ker et al, 1993; Buc et al, 1996). These ¢ndings have prompted
research into speci¢c genes underlying the predisposition to de-
pigmentation, but investigations have been complicated by the
multifactorial nature of the disorder.The involvement of multiple
genes was predicted by analyzing familial inheritance patterns
(Nordlund and Majumder, 1997).
One approach to ¢nding vitiligo-associated genes has come
from investigations showing consistent morphologic aberrancies
in melanocytes from vitiligo patients. These aberrancies include
dilated RER pro¢les in the cell and compartmentalization of
melanosomes (Boissy et al, 1991). Because these aberrancies are
maintained in patient-derived melanocyte cultures for multiple
passages, they are likely intrinisic to the pigment cell and can be
studied by comparing gene expression pro¢les for melanocytes
from vitiligo patients against those from controls. From such stu-
dies, the VIT1 gene has been identi¢ed (Le Poole et al, 2001). Re-
duced expression of theVIT1 transcript by vitiligo melanocytes is
associated with enhanced expression of the hMSH6 mismatch re-
pair gene. It has been proposed that VIT1 can regulate hMSH6
expression through the formation of RNA^RNA hybrids (Le
Poole et al, 2001). Enhanced expression is suggestive of a need
for G/T mismatch repair. Inadequate mismatch repair leaves cells
vulnerable when exposed to mutagens such as UV.
Another gene associated with vitiligo encodes catalase (Casp
et al, 2002). Mutations in or near the gene can render the cells more
susceptible to damagea ¢nding in accordance with improved
maintenance of melanocyte cultures in the presence of added cat-
alase (Medrano and Nordlund, 1990). Interestingly, family studies
have also linked vitiligo to a novel autoimmune susceptibility
gene, AIS1 (Alkhateeb et al, 2002). Moreover, genes associated
with vitiligo, as revealed by linkage analysis, include those in-
volved in antigen processing and presentation, such as LMP7,
TAP1, and CTLA-4, further supporting the involvement of an
immune mechanism in depigmentation (W.T. McCormack, per-
sonal communication).
RESISTANCE TOAPOPTOSIS
Progressive vitiligo is not associated with excessive in£ammation.
Melanocytes are thus likely eliminated by apoptosis, avoiding re-
cruitment of an in£ammatory in¢ltrate (Norris et al, 1994). Mela-
nocytes from vitiligo patients clearly exhibit resistance to
apoptosis, however, both in vitro and in vivo. High levels of Bcl-2
are found in melanocytes from both patients and controls (van
den Wijngaard et al, 2002b). Bax levels are likewise comparable
among vitiligo and control melanocytes (van den Wijngaard
et al, 2002b). In general, melanocytes from patients and controls
respond to apoptotic stimuli such as UV-B with equal levels of
cell death (van denWijngaard et al, 2002b). This is also consistent
with an equal extent of resistance to CD95L- mediated apoptosis
noted for control and vitiligo melanocytes. Melanocytes can be
induced to express cFLIP, yet resistance to CD95L-mediated
apoptosis is independent of cFLIP expression.1 These ¢ndings cu-
mulatively indicate that vitiligo melanocytes are no more prone
to apoptosis than are control melanocytes.
Interestingly, exposure to bleaching phenols induces increased
expression of the A2B receptor for adenosine speci¢cally by epi-
dermal melanocytes, and adenosine receptor expression has been
associated with increased susceptibility to apoptosis (Harning
et al, 1991). At present, it is not known whether depigmentation
following exposure involves or circumvents an immune response
to melanocytes.Where Tcells are present to mediate depigmenta-
tion, cytoxicity is likely mediated by a granzyme/perforin me-
chanism for induction of melanocyte apoptosis in vitiligo (van
den Wijngaard et al, 2002b). In this respect, perforin expression
as well as granzyme expression (Fig 2) was observed in marginal
skin from progressive vitiligo patients (van den Wijngaard et al,
2000).
DEPIGMENTATION AND SERUM AUTOANTIBODIES
The ¢rst studies linking vitiligo to autoimmune responses in-
volved the detection of serum autoantibodies to melanocytes in
vitiligo patients, with autoantibody levels elevated in patients
with progressive disease (Harning et al, 1991). Patients exhibited
serum autoantibodies reactive with melanocyte antigens (Naugh-
ton et al, 1983). In vitro studies were used to demonstrate that mel-
anocytes are vulnerable to complement-mediated killing and
ADCC (Norris et al, 1988). Complement-activated killing may
occur speci¢cally in vitiligo patients where aberrant expression
of complement regulatory proteins, membrane cofactor protein
(MCP), and decay-accelerating factor (DAF) leaves melanocytes
sensitive to complement-mediated lysis (Venneker et al, 1998; van
den Wijngaard et al, 2002a). In vivo, vitiligo serum is capable of
reducing melanocyte numbers in xenotransplanted human skin
(Gilhar et al, 1995). The revelation of multiple intracellular pro-
teins as targets for autoantibodies rendered a causative contribu-
tion of antibodies to depigmentation unlikely until the discovery
of humoral responses to membrane antigens, such as the melanin-
concentrating hormone receptor (MCH-R1) (Kemp et al, 2002).
Recognition of MCH by neighboring keratinocytes appears to
be mediated by a di¡erent receptor, leaving epidermal MCH-R1
expression restricted to melanocytes (Burgaud et al, 1997). In this
respect, the binding of antibodies to MCH-R1 theoretically con-
tributes to depigmentation by the introduction of pigment cell
damage as well as by receptor inactivation and subsequent inhibi-
tion of melanogenesis. Moreover, the melanosomal antigenTRP-
1 can be targeted because it is expressed on the cell membrane
during tra⁄cking to the melanosome (van den Wijngaard et al,
Figure1. Both arms of a generalized vitiligo (1 in mirror image)
emphasizing characteristic symmetrical distribution of depigmented
lesions.
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2001;Trcka et al, 2002). Thus, a causative role for such autoantibo-
dies to melanocytes in vitiligo etiology is entirely possible.
INFILTRATING T CELLS
T cell in¢ltrates in vitiligo have long been overlooked because
they are minute and can be found spanning the margin only in
patients with progressive disease. In exceptional cases of in£am-
matory vitiligo, in which more immunocytes in¢ltrate marginal
skin surrounding expanding lesions than in generalized vitiligo,
these in¢ltrates are more easily characterized. They have been
found to contain CD4 and CD8 T cells as well as CD68þ
macrophages, but no B cells (Le Poole et al, 1996), and invariably
they are seen at the site of depigmentation. Findings for in£am-
matory vitiligo have been extended as well to patients with gen-
eralized vitiligo, who represent the vast majority of vitiligo
patients (van denWijngaard et al, 2000). In¢ltrates have not been
described for segmental or occupational vitiligo, leaving room
for further investigation. In in£ammatory and generalized vitili-
go, cytotoxic T cells are juxtaposed to remaining melanocytes,
suggesting a causative role for them in depigmentation.
Exciting new data speci¢cally relating to vitiligo patients
further support a causative role for Tcells. T cells were propagated
from marginal skin of HLA-A2þ progressive vitiligo patients.
They were maintained without antigenic stimulation, and result-
ing cultures were characterized for cytokine pro¢les, peptide spe-
ci¢city, and cytotoxic activity toward melanocytes. These
investigations revealed that both helper and cytotoxicTcells from
progressing margins generate predominantly type 1 cytokines,
namely IFN-g andTNF-a, whereas CD8þ Tcells frequently re-
cognize the modi¢ed MART-1 peptide ELAGIGLTV. This is in
accordance with prior data showing elevated MART-1 reactivity
in peripheral blood from patients with progressive disease (Ogg
et al, 1998). Furthermore, the cytotoxicity of CD8þ Tcells toward
HLA-matched melanocytes was demonstrated (Wankowicz-
Kalinska et al, 2003).
Candidate antigens to be targeted by T cells in vitiligo were
derived from melanoma research, as most T cells in¢ltrating mel-
anoma tumors were found to respond to melanosomal di¡eren-
tiation antigens that are also expressed by normal melanocytes
(Sakai et al, 1997). These include tyrosinase, gp100, MART-1,
TRP-2, P protein, and, to a lesser extent, TRP-1 (Sakai et al,
1997). Because of their discovery as tumor-associated antigens,
these di¡erentiation markers have been targeted in numerous
immunotherapy trials to combat melanoma (Engelhard et al,
2002). As these antigens are shared among normal melanocytes
and melanoma tumor cells, it follows that immunotherapy direc-
ted against melanoma cells can lead to destruction of normal
melanocytes and result in progressive depigmentation, as demon-
strated in mice (Overwijk et al, 1999;Van Elzas et al, 2001).
Speci¢c properties of the melanosome (Marks et al, 2003) the
organelle harboring the majority of melanoma tumor^associated
antigens, may explain the immunogenic nature of these di¡eren-
tiation antigens. Interestingly, the melanosome found in melano-
cytic cells is very similar to lysosomes of other cell types. As with
lysosomes, targeting antigens to the melanosomal compartment
increases their immunogenicity (Wang et al, 1999). Although pre-
sentation of antigens is a feature of professional antigen-present-
ing cells, melanocytes are capable of presenting antigens in the
context of MHC class II molecules (Le Poole et al, 1993). Under
exceptional conditions, as in melanoma or vitiligo, melanocytic
cells become HLA-DRþ and thus present the contents of the
melanosome in the context of MHC class II (Le Poole et al, 1996;
van denWijngaard et al, 2000). These epitopes are likely excluded
from peripheral tolerance, so class II^expressing melanocytes can
become targets for cytotoxic CD4 T cells or they can activate in
situ T cell help for activation of adjacent cytotoxic CD8 T cells,
thereby breaking tolerance to CD8 epitopes (Overwijk and Res-
tifo, 2000).
Not surprisingly, melanoma-associated skin depigmentation is
considered a positive prognostic sign for melanoma patients
(Nordlund et al, 1983). Skin depigmentation represents an active
and e¡ective immune response against melanosomal di¡erentia-
tion antigens that may eliminate distant melanoma metastases
(Nordlund et al, 1983; Kawakami et al, 1998). As explained earlier,
melanoma patients treated with experimental immunotherapy
that targets melanocyte di¡erentiation antigens can develop viti-
ligo (Yee et al, 2000). T cells in¢ltrating depigmenting skin were
found to be identical to T cells in¢ltrating adjacent tumors, indi-
cating that the same cells responsible for tumor reduction are also
responsible for depigmentation (Becker et al, 2002). This leaves
the question of whether T cells are similarly responsible for de-
pigmentation when there is no malignancy and thus no obvious
reason for breaking tolerance to self antigens.
STRESS AND NEW LESIONS
Prior to the onset of progressive episodes, patients frequently ex-
perience trauma to the skin in the form of excessive UVexposure;
cuts, bruises or burns; or contact with bleaching chemicals, in-
cluding parasubstituted phenols encountered in large quantities
in occupational settings such as rubber manufacture (O’Malley
et al, 1988). Stress induces the expression of protective heat shock
proteins (HSP) and glucose-regulated proteins (GRP) that bind
cellular transcripts and proteins in order to put the cell on hold
until the stress passes.We recently reported aberrant expression of
such stress proteins, speci¢cally HSP70 and HSP27 in vitiligo
skin.2 Under excessive stress, the cytoprotective e¡ect of stress
proteins can be inadequate to prevent cell death and the proteins
spill over into the environment.When taken up by passing den-
dritic cells, stress proteins invoke an immune response speci¢cally
to chaperoned peptides and proteins (Srivastava and Amato,
2001). If these proteins are melanosomal antigens, the resulting
immune response will be directed to melanocytes. Moreover,
several stress proteins, including HSP70 and grp94, can induce
dendritic cell activation and enhance uptake of antigens and
subsequent T cell activation (Basu et al, 2002). Our ¢ndings also
indicate that stress proteins upregulate expression of ICAM-1 by
melanocytes. The signi¢cance of this ¢nding is supported by the
Figure 2. Granzyme expression detected by immunohistochemical
analysis of perilesional skin from a patient with progressive, gener-
alized vitiligo. Granzyme-expressingTcells in close proximity to the epi-
dermis, where remaining melanocytes are located, are marked with arrows.
2Le Poole IC, Curry J, Qin J, Stennett L, Nickolo¡ BJ. Role for heat
shock proteins in the immunopathogenesis of vitiligo. 63rd Annual Meet-
ing SID, Los Angeles CA, abstr. #776, 2002
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observation that ICAM-1 expression is found in the basal layer of
the epidermis of marginal vitiligo skin (Le Poole et al, 1996; van
denWijngaard et al, 2000).
A POTENTIAL CONTRIBUTION FOR
DENDRITIC CELLS
Dendritic cells were recently reported to be cytotoxic to tumor
cells, engaging TNF family members expressed on the dendritic
cell membrane to induce apoptosis in their targets (Janjic et al,
2002; Lu et al, 2002). Speci¢city for tumor cells is maintained by
expression of receptors for TNF,TRAIL, and lymphotoxin-a by
malignantly transformed target cells (Janjic et al, 2002). Interest-
ingly, upregulation of these receptors was reported for normal
keratinocytes after UV-B treatment and such keratinocytes are ef-
fectively killed by puri¢ed recombinant TRAIL (Maeda et al,
2001). It is likely, that melanocytes are similarly vulnerable to
dendritic cell^mediated killing under stress. Reduced turnover
rates for melanocytes compared to keratinocytes likely dictate
harsher consequences for the pigment cell population. Our preli-
minary observations using melanocyte cell line PIG1 targeted by
stress protein-activated dendritic cells support this concept.3
VITILIGOANDMELANOMA: FLIP SIDES OF THE
SAME COIN?
In vitiligo, an unwanted immune response to melanosomal self
antigens is triggered by stress, stimulating immunocyte in£ux
and expression of type 1 cytokines. De novo presentation of mela-
nosomal antigens in the context of MHC class II and upregula-
tion of costimulatory molecules on the surface of melanocytes
contribute to an immune response directed against melanocytes.
An overview of the autoimmune response contributing to skin
depigmentation is shown in Fig 3. In melanoma, vitiligo is con-
sidered a desirable side e¡ect of e¡ective immunity to melanocytic
cells. An increase in the abundance of melanocyte di¡eren-
tiation antigens supported by a proin£ammatory cytokine environ-
ment can overcome tolerance to self antigens. Similar to
vitiligo, de novo expression of MHC class II may factor into this
equation and enhance immunity to melanosomal antigens. Cases
have been reported, however, where depigmentation of skin and
hair were not accompanied by e¡ective tumor shrinkage (Yee
et al, 2000). Melanoma tumor cells can develop immune escape
mechanisms by downmodulation of MHC class I molecules at the
cell surface or reduced processing and presentation of target anti-
gens, leaving tumor cells invisible to in¢ltratingTcells (Marinco-
la et al, 2000). In fact, such immune escape can be the very
consequence of IFN-g secretion by activated T cells (Le Poole
et al, 2002). Cytokine-induced downmodulation of melanosomal
antigens interferes withT cell recognition of melanoma cells. Ex-
posure to IFN-g does not a¡ect recognition of normal melano-
cytes, likely because these targets retain above-threshold levels of
antigen expression. Thus, IFN-g secretion may contribute to tu-
mor escape as well as to skin depigmentation through T cell acti-
vation and reduced expression of melanogenic enzymes.
In both melanoma and vitiligo, depigmentation involves cyto-
toxic T cell in¢ltrates speci¢c to similar antigens (Wankowicz-
Kalinska et al, 2003b). Future investigations will reveal whether
an e¡ector function for dendritic cells contributes signi¢cantly
to the loss of melanocytic cells in either disease. In general, it is
of interest to further characterize the similarities as well as the
speci¢c di¡erences among target cells and immunocytes interact-
ing in either disease in order to design e¡ective therapy for both.
These studies were carried out in part under research programmes ODP-9 and ODP-
10 of the January van Loghem Institute for Immunology in the Netherlands, with
¢nancial support from Stiefel Laboratories (UK), the National Vitiligo Foundation
(USA), and the National Institutes of Health Grant IR03 AR50137-01
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